Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2026)
Lyell Immunopharma recorded quarterly Cash from Financing Activities of $51.7 million in Q1 2026, up 23198.2% quarter-over-quarter from $222000.0 in Q4 2025, and up 5172100.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $51.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 5172100.0% year-over-year to $51.7 million; the TTM figure through Mar 2026 stood at $102.1 million (up 7755.92% YoY), while the FY2025 annual figure was $50.4 million, up 3701.36% from the prior year.
- Cash from Financing Activities came in at $51.7 million for Q1 2026 at Lyell Immunopharma, up from $222000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $51.7 million in Q1 2026 to a low of -$143000.0 in Q3 2023.
- A 5-year average of $7.2 million and a median of $810500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 103.0% in 2023 and surged 5172100.0% in 2026, its largest moves.
- Lyell Immunopharma's Cash from Financing Activities stood at $863000.0 in 2022, then slipped by 12.05% to $759000.0 in 2023, then slumped by 42.42% to $437000.0 in 2024, then plunged by 49.2% to $222000.0 in 2025, then jumped by 23198.2% to $51.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $51.7 million, $222000.0, and $50.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | 51.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.72 Mn |
| Mar 31, 2026 | 51.72 Mn |
| Dec 31, 2025 | 222,000.00 |
| Dec 31, 2025 | 222,000.00 |
| Sep 30, 2025 | 50.00 Mn |
| Sep 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 437,000.00 |
| Dec 31, 2024 | 437,000.00 |
| Jun 30, 2024 | 862,000.00 |
| Jun 30, 2024 | 862,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 759,000.00 |
| Dec 31, 2023 | 759,000.00 |
| Sep 30, 2023 | -143,000.00 |
| Sep 30, 2023 | -143,000.00 |
| Jun 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | -69,000.00 |
| Mar 31, 2023 | -69,000.00 |
| Dec 31, 2022 | 863,000.00 |
| Dec 31, 2022 | 863,000.00 |
| Sep 30, 2022 | 4.76 Mn |
| Sep 30, 2022 | 4.76 Mn |
| Jun 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 2.46 Mn |
| Mar 31, 2022 | 2.56 Mn |
| Mar 31, 2022 | 2.56 Mn |
| Dec 31, 2021 | 7.40 Mn |
| Dec 31, 2021 | 7.40 Mn |
| Sep 30, 2021 | -531,000.00 |
| Sep 30, 2021 | -531,000.00 |
| Jun 30, 2021 | 393.49 Mn |
| Jun 30, 2021 | 393.49 Mn |
| Mar 31, 2021 | 884,000.00 |
| Mar 31, 2021 | 884,000.00 |
| Dec 31, 2020 | 338,000.00 |
| Dec 31, 2020 | 338,000.00 |
| Sep 30, 2020 | 35,000.00 |
| Sep 30, 2020 | 35,000.00 |